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EDITORIAL 
The Carcinogenicity and Mutagenicity of Therapeutic Coal Tar-A 
Perspective 
Coal tar is an ill-defined, aromatic, complex brown-black 
substance resulting from the destructive distillation of coal. 
Depending upon the condi tions (temperature and pressW"e) 
under which the coal is combusted, myriad numbers of poly-
aromatic hydrocal"bons al"e generated. Polyal"Omatic or poly-
cyclic hydrocarbons are among the oldest known skin carcino-
gens. In 1775, Percival Pott, a London sW"geon, first showed 
that a specific type of skin neoplasm (scrotal cancer) preferen-
tially occurred in chimney sweeps as a result of their chronic 
exposW"e to soot [1]. H e also pointed out the lengthy laten t 
period (years) between the onset of exposure a nd the develop-
ment of overt neoplasia. 
Experimental studies early in the 20th century showed une-
quivocally that crude coal tar had oncogenic properties in rabbit 
skin [2]. Subsequently several polyaromatic hydrocru'bons were 
isolated from coal tar, pW"ified and shown to be potent skin 
clucinogens in mice [3]. Among the best known of these chem-
icals extracted fTom coal tar is benzo(a)pyrene, a ubiquitous 
environmental pollutant that is generated whenever fossil fuels 
are combusted. Despite the identification of a few constituents, 
coal tal" remains for the most part a poorly chru'acterized and 
extremely complex mixture containing at least 10,000 structW"al 
compounds. 
The carcinogenicity of coal tar products for human skin has 
been amply confirmed in numerous studies. Perhaps the most 
complete statistical data verifying the oncogenicity of coal tar 
has come from the study reported by H enry in Britain [3]. He 
showed that between 1925 and 1943 more than 3,700 cutaneous 
can cers had been reported among factory workers there. Of 
these, at least 2,200 were due to exposure to vru'ious coal tar 
products. Henry reemphasized Pott's initial observation that 
cruonic (15-25 yr) repetitive exposW"e to high concentrations of 
coal tar products was required to evoke human skin cancer . 
The neoplasms were predominantly squamous cell carcinomas 
and t hey OCCUlTed almost exclusively on the head and neck, the 
arm s, and the scrotum. 
Unlike occupational exposures, the carcinogenicity of coal tar 
products used therapeutically remains unclear. Hodgson re-
ported a single case of a squamous cell carcinoma which devel-
oped in the perianal area of a man with prUl'itus who had 
repetitively applied a coal tar product for 7 yr [4]. Subsequently, 
Rook, Gresham, and David reported a patient who developed 
2 s quamous cell carcinomas of the skin of the thigh after 32 yr 
of treatment with a solution containing coal tar [5]. Their 
review of the literatW"e in 1957 indicated that at least 6 cases of 
skin cancer related to chronic topical application of coal tru' had 
been reported. More recently Greither, Gisbertz, and Ippeh 
found a total of 13 cases of human skin cancer that were 
probably related to the prolonged use of therapeutic coal tar 
preparations [6]. 
Perhaps the most widely used therapeutic regimen utilizing 
coal tar is the Goeckerman regimen. This modality has been 
the mainstay of the treatment of moderate to severe psoriasis 
for more than 50 y]·s. It generally involves daily application of 
cru de coal tar in concentrations of 2-5% and its partial removal 
prior to incremental doses of ultraviolet light. 
Although most aut hors agree that the acute toxicity of the 
Goeckerman regimen (ultraviolet erythema and folliculitis) is 
minimal, there is concern a bout the long-term hazards of re-
peated skin exposW"e to the 2 separate oncogenic agents that 
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constitute the modality (coal tar and UVB) . Despite this con-
cern, virtually nothing is known about the skin carcinogenicity 
of the Goeckerman regimen in human populations. Recently, 
Stern et al reported an increased risk of skin cancer in psoriatic 
patients exposed for many years to large amounts of coal tru' 
and ultraviolet light [7]. This was based upon patient recall of 
the degree of prior exposure. However, Muller et al reviewed 
their experience at the Mayo Clinic with patients treated with 
the Goeckerman regim en [8] and were unable to detect any 
difference in cancer incidence in their patients as compared to 
data obtained in the National Cancer SUl-vey. In summary, the 
carcinogenicity of coal tar for the skin of experimental animals, 
and for the skin of human workers chronically exposed to large 
amounts of the material is unquestioned, whereas the risk of 
developing cancer from the use of therapeutic coal tar products 
remains unclear. 
In recent years great efforts have been made to develop short-
term procedures for the evaluation or screening of chemicals 
for their oncogenic potential, particularly since carcinogenicity 
studies in experim ental animals are extremely expensive and 
tinle-consuming. According to the somatic mutation theory of 
chemical cal'cinogenesis, t he initiation of a tumor requires that 
a n irreversible change occur in cellular DNA and it is this 
change t hat ultimately may result in unregulated proliferation 
of cells and the development of a tumor. Chemical compounds 
known to be carcinogenic would, according to the somatic 
mutation theory, be expected to be mutagenic. Stated another 
way, all carcinogens should be mutagens. 
Among the convenient experimental systems available for 
screening the mutagenicity of chemicals are microorga nisms. 
An early screening procedure developed for the study of ch em -
ical mutagenicity utilized the ability of a substance to mutate 
bacteria from streptomycin-dependence to streptomycin inde-
pendence. More, recently Ames et al have developed a series of 
tester strains of S . typh imurium which have provided a most 
convenient assay system for assessing mutagenesis [9, 10]. 
Briefly, these 'bacteria aTe unable to gl'ow in minimal media 
because of a genetic defect in the pathway of histidine biosyn-
thesis. For the assay, bacteria aTe gl'own with trace amounts of 
histidine which permits an initial brief period of growth of the 
histidine-dependent bacteria so as to provide a "tal'get" for t he 
chemical compound to be tested. Damage. to DNA, caused by 
the chemical, results in a mutation which is expressed as a 
functional gene product: in t his case, reversal of defective 
histidine synthesis (reverse mutation). Revertants to histidine-
independence are seen as colonies gl'owing on the surface of the 
histidine-poor agar. Mutagenesis is expressed as a ratio of the 
number of colonies on the plate containing the test chemical 
compared to plates without the test chemical (spontaneous 
mutants). Ames selected several tester strains of S. typhimu-
rium including T A 1535 which detects mutations resulting from 
base substitut ions a nd TA 1538 which detects frameshift mu'-
tations. l"urther refinements have yielded strains known as T A 
100 and T A 98 which ru'e even more sensitive. This enhanced ' 
mutagenic sensitivity resu lts from induced alterations in the 
lipopolysaccharide cell wall which enhances the permeability 
of the bacteria to test chemicals, to the deletion of the enzyme 
system responsible for excision repair of damaged DNA and to 
the incorporation of an R-factor (plasmid containing antibiotic 
resistance genes) which is associated with error-prone recom-
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bination repair. All of these modifications enhance the sensitiv-
ity of the bacteria to mutagenesis. These tester strains devel-
oped by Ames provide a simple, inexpensive and highly sensi-
tive assay procedure that is extremely useful in screening large 
numbers of chemical compounds. Other techniques using eu-
karyotic cells in addition to prokaryotes have also been devel-
oped in recent years [11]. 
With the extensive use of the Ames assay in the 1970's, it was 
soon recognized that there was considerable disparity between 
the mutagenicity and the carcinogenicity of certain compounds. 
Thus some chemical agents that were clearly carcinogenic in 
experimental animals had no demonstrable mutagenicity in the 
Ames assay. Because it became known that certain chemical 
carcinogens undergo metabolic transformation into reactive 
species that are the ultimate carcinogenic moieties. Ames mod-
ified his assay system by incorporating a source of microsomal 
enzymes (rat liver 9,000 xg supernatant). This modification 
greatly enhanced the sensitivity and specificity of the procedure 
such that 90% of a large series of chemical carcinogens were 
shown to be mutagenic in the Salmonella test. Conversely, most 
mutagenic chemicals are carcinogens. These findings have 
greatly strengthened the validity of the somatic mutation the-
ory of chemical carcinogenesis. Although long-term animal and 
human studies are the only ones capable of providing conclusive 
evidence concerning the carcinogenic effects of a chemical, 
short-term tests such as the Ames assay provide a screening 
procedure that can quickly evaluate large numbers of chemicals 
to which humans are exposed. ·However, it is also important to 
emphasize that no correlation can be made between the quan-
titative aspects of carcinogenicity and mutagenicity [12]. In fact 
in at least one study in which 25 polyaromatic hydrocarbons 
were tested for mutagenicity using the Ames assay, only 58% of 
the compounds demonstrated a positive correlation between 
carcinogenicity and mutagenicity [13]. Thus, to maximize the 
predictive value of short-term tests it is imperative that multiple 
types of assay procedures be used. 
It is extremely hazardous to extrapolate data obtained in 
short-term tests in prokaryotes to lifetime studies in eukaryotes 
(animal studies). It should be equally apparent that extrapola-
tion of animal data to the human population is also fraught 
with difficulty. It is of interest, however, that at present, most 
mutagenicity data relating to short-term tests extrapolate rea-
sonably well to the carcinogenic potency of a compound in 
animal t,ests. 
Elsewhere in this issue of the Journal, Wheeler, Saperstein, 
and Lowe have reported that urine extracts prepared from 
patients undergoing Goeckerman therapy contain unidentified 
ma terial(s) that is mutagenic in the Ames assay [14]. Mutagen-
icity of human urine extracts has been previously reported in 
patients treated with the trichomonacide, metronidazole, and 
the antischistosomal agent, niridazole,' as well as in urine from 
cigal'ette smokers. Furthermore, urine from children wearing 
pajamas treated with the flame retardant mutagenic chemical 
2,3-dibromopropyl phosphate (tris-BP) was found to contain 
2,3-dibromopropanol, a known metabolite of tris-BP. 
Crude coal tar is a complex mixture rich in polyaromatic 
hydrocarbons among them benzo(a)pyrene, benz(a)anthracene 
and dibenz(a,h)anthracene each of which is a known skin car-
cinogen and each of which has been showri to be mutagenic in 
the Ames assay. For example, it is estimated that therapeutic 
coal tar preparations may contain anywhere from 0.05 to 0.9% 
benzo(a)pyrene by weight. Saperstein and Wheeler have pre-
viously shown that as little as 100 fJog of crude coal tar is 
mutagenic in the Ames assay [15]. Many patients with psoriasis 
undergoing the Goeckerman regimen may be treated with the 
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topical application of several hundred grams of crude coal tar 
daily and it is not surprising that trace amounts of this material 
could be absorbed into the body. The studies of Wheeler, 
Saperstein, and Lowe unfortunately have not identified the 
mutagenic material in the urine extracts of the patients. Is it 
simply trace amounts of absorbed coal tar, is it one or several 
chemical constituents of the tar or is it metabolites of these? 
It is imperative to maintain a clear perspective in interpreting 
the significance of the findings of Wheeler, Saperstein, and 
Lowe. The presence of unidentified mutagenic material(s) in 
the urine of patients treated with coal tar is a most interesting 
and important observation. It reinforces the necessity to con-
tinue careful surveillance of all patients treated with these 
agents. These preliminary fmdings should not, however, dis-
courage the use of coal tar products in the management of 
patients with dermatologic disease who are appropriate candi-
dates for the use of these drugs. Many therapeutic agents that 
are widely used in medical practice have significant potential to 
cause toxic effects. The risk:benefit ratio must always be con-
sidered in selecting any potentially harmful treatment for hu-
man disease. At this time the beneficial effects of coal tar 
products continue to outweigh the risks associated with their 
use. In the future it is hoped that newer and potentially less 
toxic-treatment modalities will be developed thereby rendering 
obsolete the use of coal tar products. 
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